| Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers AB Rajput, MA Miller, A De Luca, N Boyd, S Leung, A Hurtado-Coll, ... Journal of clinical pathology 60 (11), 1238-1243, 2007 | 233 | 2007 |
| Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ... JAMA oncology 6 (9), 1405-1409, 2020 | 176 | 2020 |
| Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, ... Clinical Cancer Research 26 (17), 4454-4459, 2020 | 134 | 2020 |
| Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells PD Deeble, ME Cox, HF Frierson Jr, RA Sikes, JB Palmer, RJ Davidson, ... Cancer research 67 (8), 3663-3672, 2007 | 73 | 2007 |
| PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15 JW Peacock, J Palmer, D Fink, S Ip, EM Pietras, ALF Mui, SW Chung, ... Molecular and cellular biology 29 (5), 1222-1234, 2009 | 53 | 2009 |
| A major site of expression of the ets transcription factor Elf5 is epithelia of exocrine glands EJ Lapinskas, J Palmer, S Ricardo, PJ Hertzog, A Hammacher, ... Histochemistry and cell biology 122, 521-526, 2004 | 53 | 2004 |
| Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors LA Wafa, J Palmer, L Fazli, A Hurtado-Coll, RH Bell, CC Nelson, ... Human pathology 38 (1), 161-170, 2007 | 51 | 2007 |
| Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy O Klein, D Kee, B Markman, MS Carlino, C Underhill, J Palmer, D Power, ... Cancer Cell 39 (5), 592-593, 2021 | 43 | 2021 |
| Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells J Palmer, PJ Hertzog, A Hammacher The international journal of biochemistry & cell biology 36 (11), 2258-2269, 2004 | 30 | 2004 |
| Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538 O Klein, C Senko, MS Carlino, B Markman, L Jackett, B Gao, C Lum, ... Oncoimmunology 10 (1), 1908771, 2021 | 29 | 2021 |
| Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo J Palmer, M Ernst, A Hammacher, PJ Hertzog The Prostate 62 (3), 282-289, 2005 | 24 | 2005 |
| Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian … KA Figueiredo, JB Palmer, AL Mui, CC Nelson, ME Cox Annals of the New York Academy of Sciences 1041 (1), 320-327, 2005 | 20 | 2005 |
| The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate J Palmer, V Venkateswaran, NE Fleshner, LH Klotz, ME Cox The Prostate 68 (4), 345-353, 2008 | 16 | 2008 |
| ATIM-23. Preliminary findings of a phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma H Gan, L Cher, P Inglis, Z Lwin, E Lau, U Ackermann, N Coombs, ... Neuro-Oncology 21 (Supplement_6), vi6-vi6, 2019 | 13 | 2019 |
| Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial O Klein, D Kee, B Gao, B Markman, J da Gama Duarte, L Quigley, ... Journal for Immunotherapy of Cancer 9 (11), 2021 | 7 | 2021 |
| Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers. O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, C Lum, ... Journal of Clinical Oncology 38 (15_suppl), 4588-4588, 2020 | 7 | 2020 |
| A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases S Arulananda, S Parakh, J Palmer, M Goodwin, MC Andrews, J Cebon Cancer Reports 2 (4), e1183, 2019 | 7 | 2019 |
| A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies. O Klein, D Kee, B Markman, R Chang Lee, M Michael, LR Mileshkin, ... Journal of Clinical Oncology 37 (15_suppl), 2570-2570, 2019 | 7 | 2019 |
| Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma H Gan, L Cher, PL Inglis, Z Lwin, E Lau, C Wichmann, U Ackermann, ... Journal of Nuclear Medicine 62 (supplement 1), 104-104, 2021 | 4 | 2021 |
| Phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma H Gan, L Cher, P Inglis, Z Lwin, E Lau, C Wichmann, A McDonald, ... Journal of Nuclear Medicine 61 (supplement 1), 1562-1562, 2020 | 3 | 2020 |
